|1.||Timke, Carmen: 3 articles (07/2012 - 06/2011)|
|2.||Lahn, Michael: 3 articles (07/2012 - 06/2011)|
|3.||Wirkner, Ute: 3 articles (07/2012 - 06/2011)|
|4.||Huber, Peter E: 3 articles (07/2012 - 06/2011)|
|5.||Peschke, Peter: 3 articles (07/2012 - 06/2011)|
|6.||Yingling, Jonathan M: 3 articles (03/2012 - 01/2010)|
|7.||Antonaci, Salvatore: 3 articles (07/2011 - 10/2009)|
|8.||Fransvea, Emilia: 3 articles (07/2011 - 10/2009)|
|9.||Giannelli, Gianluigi: 3 articles (07/2011 - 10/2009)|
|10.||Mazzocca, Antonio: 3 articles (07/2011 - 10/2009)|
02/01/2010 - "LY2109761 interrupts the cross-talk between cancer cells and cancer-associated fibroblasts, leading to a significant reduction of HCC growth and dissemination. "
03/01/2012 - "In addition, LY2109761 treatment significantly inhibited the growth of MDA PCa 2b and PC-3 in the bone of SCID mice (p<0.05); moreover, it resulted in significantly less bone loss and change in osteoclast-associated parameters in the PC-3 tumor-bearing bones than in the untreated mice. "
12/01/2011 - "Histologic analyses showed that LY2109761 inhibited tumor invasion promoted by radiation, reduced tumor microvessel density, and attenuated mesenchymal transition. "
12/01/2011 - "In an orthotopic intracranial model, LY2109761 significantly reduced tumor growth, prolonged survival, and extended the prolongation of survival induced by radiation treatment. "
06/01/2011 - "LY2109761 also reduced tumor blood perfusion as quantified by noninvasive dynamic contrast-enhanced magnetic resonance imaging. "
|2.||Neoplasm Metastasis (Metastasis)
04/01/2015 - "Our data indicate that LY2109761 suppresses OS metastasis and enhanced chemosensitivity by targeting S100A4. "
04/01/2015 - "Here, we investigated the role and mechanism of LY2109761 on metastasis and chemosensitivity of OS MG-63 cells. "
05/08/2009 - "Furthermore, LY2109761 decreases liver metastases and prolongs survival in an experimental metastasis model. "
04/01/2015 - "LY2109761 may have important implications for the development of strategies for inhibiting metastasis and overcoming OS cell resistance to chemotherapy."
04/01/2015 - "LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells."
03/15/2011 - "However, molecular analysis of resultant carcinomas by microarray gene expression, Western blotting, and immunohistochemistry suggests that long-term LY2109761 exposure leads to the outgrowth of carcinomas with elevated P-Smad2 levels that do not respond to drug. "
03/15/2011 - "Sustained exposure to LY2109761 (100 mg/kg/d) throughout the tumor outgrowth phase had no effect on carcinoma latency or incidence. "
03/15/2011 - "In the 7,12-dimethyl-benzanthracene plus phorbol myristate acetate-induced skin chemical carcinogenesis model, acute dosing of established naive primary carcinomas with LY2109761 (100 mg/kg) every 8 hours for 10 days (100 mg/kg) diminished phospho-Smad2 (P-Smad2) levels and marginally decreased the expression of inflammatory and invasive markers. "
03/15/2011 - "Systemic LY2109761 administration disrupted tumor vascular architecture and reduced myofibroblast differentiation of E4 skin carcinoma cells in a tumor allograft. "
03/15/2011 - "Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761."
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/2008 - "We hypothesized that targeting TbetaRI/II kinase activity with the novel inhibitor LY2109761 would suppress pancreatic cancer metastatic processes. "
04/01/2008 - "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis."
04/01/2008 - "The efficacy of LY2109761 on tumor growth, survival, and reduction of spontaneous metastasis have been evaluated in an orthotopic murine model of metastatic pancreatic cancer expressing both luciferase and green fluorescence proteins (L3.6pl/GLT). "
|5.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2015 - "LY2109761 was sufficient to induce spontaneous apoptosis of ovarian cancer cells. "
01/01/2015 - "Chemotherapeutic approaches using LY2109761 might enhance the treatment benefit of the cisplatin in the treatment of ovarian cancer patients."
01/01/2015 - "Combination with LY2109761 significantly augmented the cytotoxicity of cisplatin in both parental and cisplatin resistant ovarian cancer cells. "
01/01/2015 - "LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells."
01/01/2015 - "Combination treatment of LY2109761 and cisplatin showed antiproliferative effects and induced a greater rate of apoptosis than the sum of the single-treatment rates and promoted tumor regression in established parental and cisplatin resistant ovarian cancer xenograft models. "
|2.||Transforming Growth Factor beta Receptors (TGF beta Receptors)
|3.||Proteins (Proteins, Gene)
|4.||RNA (Ribonucleic Acid)
|6.||Transforming Growth Factor beta (TGF-beta)
|9.||Transforming Growth Factor beta1 (TGF beta 1)
|10.||Cyclooxygenase 2 (Cyclooxygenase-2)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Homologous Transplantation (Allograft)
|4.||Drug Therapy (Chemotherapy)